The stock of CombiMatrix Corp (NASDAQ:CBMX) is a huge mover today! About 67,361 shares traded hands. CombiMatrix Corp (NASDAQ:CBMX) has declined 55.29% since March 7, 2016 and is downtrending. It has underperformed by 62.88% the S&P500.
The move comes after 8 months negative chart setup for the $6.52 million company. It was reported on Oct, 10 by Barchart.com. We have $2.54 PT which if reached, will make NASDAQ:CBMX worth $717,200 less.
Analysts await CombiMatrix Corp (NASDAQ:CBMX) to report earnings on November, 2. They expect $-1.07 earnings per share, up 45.13% or $0.88 from last year’s $-1.95 per share. After $-0.89 actual earnings per share reported by CombiMatrix Corp for the previous quarter, Wall Street now forecasts 20.22% negative EPS growth.
According to Zacks Investment Research, “CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in potential markets where their products and services can be utilized. The Company’s products and services are specially utilized in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets. The technologies they have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.”
More recent CombiMatrix Corp (NASDAQ:CBMX) news were published by: Marketwatch.com which released: “CombiMatrix’s stock soars 21% premarket after distribution agreement announced” on February 24, 2011. Also Quotes.Wsj.com published the news titled: “CombiMatrix Corp. CBMX (US: Nasdaq)” on February 11, 2011. Seekingalpha.com‘s news article titled: “CombiMatrix Corporation’s (CBMX) CEO Mark McDonough Q2 2016 Results – Earnings …” with publication date: August 04, 2016 was also an interesting one.
CBMX Company Profile
CombiMatrix Corporation, incorporated on July 11, 2000, is a well-known provider of molecular diagnostic solutions. The Firm specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid (DNA) testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. The Firm performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis (CMA), fluorescence in situ hybridization (FISH) and karyotyping. The Firm also holds interests in Leuchemix, Inc., which is a drug development firm focused on developing a series of compounds to address a number of oncology-related diseases. The Firm develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (also referred to as products of conception analysis (POC)), prenatal genetics and postnatal developmental disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.